Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 0.84 |
| ▸ | CCNA2 | P20248 | 19/20 | 0.84 |
| ▸ | CCNA1 | P78396 | 14/20 | 0.84 |
| ▸ | AURKA | O14965 | 12/20 | 0.84 |
| ▸ | PLK1 | P53350 | 8/20 | 0.84 |
| ▸ | CDK4 | P11802 | 8/20 | 0.68 |
| ▸ | CCND3 | P30281 | 8/20 | 0.68 |
| ▸ | CDK6 | Q00534 | 8/20 | 0.68 |
| ▸ | TTK | P33981 | 2/20 | 0.68 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.68 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4158625 | 0.91 | CCNA2 (1.00) | CDK2CCNA2CCNA1AURKAPLK1 | |
| SCHEMBL6052853 | 0.89 | CDK2 (0.84) | CDK2CCNA2CCNA1AURKAPLK1 | |
| SCHEMBL4154945 | 0.89 | CDK2 (1.00) | CDK2CCNA2CCNA1AURKAPLK1 | |
| SCHEMBL4157378 | 0.88 | CDK2 (0.82) | CDK2CCNA2CCNA1AURKAPLK1 | |
| SCHEMBL31326959 | 0.88 | CDK2 (0.82) | CDK2CCNA2CCNA1AURKAPLK1 | |
| SCHEMBL1894768 | 0.83 | PLK1 (0.84) | CDK2CCNA2CCNA1AURKAPLK1 | |
| SCHEMBL18798566 | 0.82 | CDK2 (0.78) | CDK2CCNA2CCNA1AURKAPLK1 | |
| SCHEMBL6053129 | 0.80 | CCNA2 (0.70) | CDK2CCNA2CCNA1AURKAPLK1 | |
| SCHEMBL4158641 | 0.80 | CCNA2 (0.85) | CDK2CCNA2CCNA1AURKAPLK1 | |
| SCHEMBL4152035 | 0.80 | CDK2 (1.00) | CDK2CCNA2CCNA1AURKAPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300935-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Nerviano Medical Sciences, S.R.L. (IT) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300935-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | CDK2 49/4885CCNA2 1207/4885CCNA1 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.